BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thorens B, Rodriguez A, Cruciani-Guglielmacci C, Wigger L, Ibberson M, Magnan C. Use of preclinical models to identify markers of type 2 diabetes susceptibility and novel regulators of insulin secretion - A step towards precision medicine. Mol Metab 2019;27S:S147-54. [PMID: 31500826 DOI: 10.1016/j.molmet.2019.06.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fenske RJ, Weeks AM, Daniels M, Nall R, Pabich S, Brill AL, Peter DC, Punt M, Cox ED, Davis DB, Kimple ME. Plasma Prostaglandin E(2) Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation. Metabolites 2022;12. [PMID: 36557272 DOI: 10.3390/metabo12121234] [Reference Citation Analysis]
2 Luís C, Baylina P, Soares R, Fernandes R. Metabolic Dysfunction Biomarkers as Predictors of Early Diabetes. Biomolecules 2021;11:1589. [PMID: 34827587 DOI: 10.3390/biom11111589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sánchez-Archidona AR, Cruciani-Guglielmacci C, Roujeau C, Wigger L, Lallement J, Denom J, Barovic M, Kassis N, Mehl F, Weitz J, Distler M, Klose C, Simons K, Ibberson M, Solimena M, Magnan C, Thorens B. Plasma triacylglycerols are biomarkers of β-cell function in mice and humans. Mol Metab 2021;54:101355. [PMID: 34634522 DOI: 10.1016/j.molmet.2021.101355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Carrard J, Gallart-Ayala H, Weber N, Colledge F, Streese L, Hanssen H, Schmied C, Ivanisevic J, Schmidt-Trucksäss A. How Ceramides Orchestrate Cardiometabolic Health-An Ode to Physically Active Living. Metabolites 2021;11:675. [PMID: 34677390 DOI: 10.3390/metabo11100675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Macášek J, Zeman M, Žák A, Staňková B, Vecka M. Altered Indices of Fatty Acid Elongases ELOVL6, ELOVL5, and ELOVL2 Activities in Patients with Impaired Fasting Glycemia. Metab Syndr Relat Disord 2021;19:386-92. [PMID: 33983851 DOI: 10.1089/met.2021.0012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chaurasia B, Summers SA. Ceramides in Metabolism: Key Lipotoxic Players. Annu Rev Physiol 2021;83:303-30. [PMID: 33158378 DOI: 10.1146/annurev-physiol-031620-093815] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
7 Tanabe H, Saito H, Kudo A, Machii N, Hirai H, Maimaituxun G, Tanaka K, Masuzaki H, Watanabe T, Asahi K, Kazama J, Shimabukuro M. Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups: A Japanese Retrospective Cohort Study. J Clin Med 2020;9:E2083. [PMID: 32630741 DOI: 10.3390/jcm9072083] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
8 Poss AM, Summers SA. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD. Front Endocrinol (Lausanne) 2020;11:505. [PMID: 32849291 DOI: 10.3389/fendo.2020.00505] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]